Psikofarmakolojinin Tarihsel Gelişimi
Özet
Psikofarmakoloji tarihi, antik çağlardaki bitkisel kökenli öncüllerden modern biyolojik tedavilere uzanan dinamik bir süreci kapsar. Eski uygarlıklarda afyon, hellebore ve yılan kökü gibi maddeler ruhsal sorunları yatıştırmak ve fiziksel dengesizlikleri düzeltmek amacıyla kullanılmıştır. Orta Çağ Avrupası'nda ruhsal hastalıklar dini inanışların etkisiyle gerileme dönemine girerken, İslam dünyasında El-Biruni ve İbn-i Sina gibi hekimler Hipokratik geleneği sürdürerek tıbbi çalışmaları ilerletmiştir. 19. yüzyılda Pinel ve Esquirol gibi isimlerin öncülüğünde insani reformlar başlamış, akıl hastanelerindeki acımasız yöntemlere son verilmiştir. Psikofarmakolojide asıl devrim, 1950'lerin başında anestezi çalışmalarından ilham alınarak klorpromazinin rastlantısal keşfiyle gerçekleşmiştir. Bu gelişme, şizofreni ve manik durumların tedavisinde çığır açarak hastaların taburcu edilmesini ve akıl hastanelerinin daha huzurlu alanlara dönüşmesini sağlamıştır. Ardından tüberküloz araştırmaları sırasında ilk antidepresan olan iproniazid ve manik ataklar için lityum keşfedilmiştir. 1950'li yıllarda meprobamat ve 1960'larda benzodiazepinlerin bulunması anksiyete tedavisinde önemli adımlar olmuştur. Son otuz yılda ise daha az yan etki profiline sahip ikinci kuşak antipsikotikler, yeni nesil antidepresanlar (SSGİ ve SSNGİ) ve Alzheimer hastalığına yönelik kolinerjik hipoteze dayalı hedefe yönelik tedaviler geliştirilmiştir. Günümüzde psikofarmakoloji, genetik ve epigenetik ilerlemeler ışığında bireye özgü tedavi modellerine odaklanmaktadır.
The history of psychopharmacology spans a dynamic process extending from herbal antecedents in ancient times to modern biological treatments. In ancient civilizations, substances such as opium, hellebore, and snakeroot were utilized to soothe mental problems and correct physical imbalances. While mental illnesses entered a period of decline in Medieval Europe due to the influence of religious beliefs, physicians in the Islamic world like Al-Biruni and Avicenna advanced medical studies by sustaining the Hippocratic tradition. In the 19th century, humane reforms commenced under the leadership of figures like Pinel and Esquirol, putting an end to cruel methods in mental asylums. The actual revolution in psychopharmacology occurred in the early 1950s with the accidental discovery of chlorpromazine, inspired by anesthesia studies. This development pioneered a breakdown in the treatment of schizophrenia and manic states, enabling the discharge of patients and transforming mental hospitals into more peaceful spaces. Subsequently, iproniazid, the first antidepressant, was discovered during tuberculosis research, along with lithium for manic episodes. The introduction of meprobamate in the 1950s and benzodiazepines in the 1960s marked significant steps in anxiety treatment. Over the last thirty years, second-generation antipsychotics with lower side effect profiles, new-generation antidepressants (SSRIs and SNRIs), and targeted treatments based on the cholinergic hypothesis for Alzheimer's disease have been developed. Today, psychopharmacology focuses on personalized treatment models in light of genetic and epigenetic advancements.
Referanslar
Aragón-Poce F, Martı́nez-Fernández E, Márquez-Espinós C, et al. History of opium. In International Congress Series Elsevier. 2002;1242:19-21.
Sneader W. The prehistory of psychotherapeutic agents. Journal of Psychopharmacology. 1990; 4(3): 115-119.
Spiegel R. The history of Psychopharmacology, Psychopharmacology: An introduction. Fourth edition., Chichester, England, John Wiley and Sons Ltd. 2003; 27-97
Frankenburg FR. History of the development of antipsychotic medication. Psychiatr Clin North Am. 1994; 17(3):531-40. PMID: 7824380.
Bhatara VS, Sharma JN, Gupta S, & Gupta YK. Images in psychiatry. Rauwolfia serpentina: the first herbal antipsychotic. The American journal of psychiatry. 1997; 154(7): 894.
Colp R. History ofpsychiatry. Comprehensive Textbook of Psychiatry, BJ Sadock, VA Sadock, P Ruiz (Eds), ninth edition, Philidelphia, Lippincott Williams & Wilkins,s. 2009; 4474-5509
Köknel Ö. Modern Psikofarmakolojinin Ellinci Yılında Türkiye’de ve Dünyada Psikofarmakoloji ve Psikofarmakolojik Araştırmaların Tarihçesi. Klinik Psikofarmakoloji Bülteni. 2002; 12: 201-210.
Caldwell AE. History of psychopharmacology. Principles of psychopharmacology. 1978; 2.
Berrios G, & Porter R. A history of clinical psychiatry: the origin and history of psychiatric disorders. In Uma história da psiquiatria clínica: a origem e a história dos transtornos psiquiátricos. Vol. 2: As psicoses funcionais. 2012; 677-677.
López-Muñoz F, Ucha-Udabe R, Alamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatric disease and treatment. 2005; 1(4): 329.
Prudic J. Electro-convulsive therapy. Comprehensive Textbook of Psychiatry, BJ Sadock, VA Sadock, P Ruiz (Eds), Ninth edition, Lippincott Williams & Wilkins. Philadelphia. 2009; 3285.
Caldwell AE. Origins of psychopharmacology: From CPZ to LSD. 1970.
Swazey JP. Chlorpromazine in Psychiatry, MIT Press, Cambridge, MA, 1974.
Ayd FJ. The early history of modern psychopharmacology. Neuropsychopharmacology (New York, NY). 1991; 5(2): 71-84.
López-Muñoz F, Alamo C, Cuenca E, et al. History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry. 2005; 17(3): 113-135.
Cancro R. The introduction of neuroleptics: a psychiatric revolution. Psychiatric Services. 2000; 51(3): 333-335
Kuhn R. The Imipramine Story in" Discoveries in Biological Psychiatry". FJ Ayd, B Blackwell (Eds),Philadelphia, Lippincott. 1970; 005-217.
Pletscher A. The discovery of antidepressants: a winding path. Experientia. 1991; 47(1): 4-8.
Cade FJF. The story of lithium. Discoveries in Biological Psychiatry: rauwolfia serpentina: the first herbal antipsychotic, FJ Ayd, B Blackwell (Eds), Philadelphia, Lippincott. 1970; 218-229.
Johnson FN. The history of lithium therapy. Springer. 1984.
Strobusch AD, Jefferson JW. The checkered history of lithium in medicine. Pharmacy in history. 1980; 22(2): 72-76.
Bech P. The full story of lithium (1918–2005). Atribute to Mogens Schou. Psychother Psychosom. 2006; 75: 265-269.
Ban TA. Psychopharmacology. Williams & Wilkins, Baltimore. 1969.
Sternbach LH. The benzodiazepine story. Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques. 1978; 229-266.
Schmutz J, Eichenberger E. Clozapine. In: Bindra, J.S., Ledniger, D. (eds): Chronicles of Drug Discovery. John Wiley. New York. 1983; 39–59.
Lehmann HE, Ban TA. The history of the psychopharmacology of schizophrenia. The Canadian Journal of Psychiatry. 1997; 42(2): 152-162.
McKenna P, Bailey P. The Strange Story of Clozapine. British Journal of Psychiatry. 1993; 162(1): 32-37. doi:10.1192/S0007125000131691
Kane J, Honigfeld G, Singer J. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of general psychiatry. 1988; 45(9): 789-796.
Owens MJ, Risch SC. Atypical Antipsychotics. Textbook of Pysychopharmacology, AF Schatzberg, NemeroffCB (Eds), second edition, Washington DC, American Pychiatric Press. 1998; 328-348.
Gupta S, Black DW, Smith DA. Risperidone: review of its pharmacology and therapeutic use in schizophrenia. Annals of Clinical Psychiatry. 1994; 6(3): 173-180.
Tupper D, Hotten T, Moore N. Presentation on olanzapine, given at the Society for Medicines Research Millenial Case Histories of Drug Discovery and Design Meeting, London. 1999.
Gupta S, Masand P. Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders. Annals of clinical psychiatry. 2004; 16(3): 155-166.
Carlsson A, Gottfries CG, Holmberg G, et al. Recent advances in the treatment of depression. Acta Physiol. Scand. Suppl. 1981; 290.
Angst J, Amrein R & Stagbl M. Moclobemide: a paradigm of research in clinical psychopharmacology. European Psychiatry. 1996;11(S4):219-219.
Healy D. The antidepressant era. Harvard University Press. 1997.
Bowen DM, Smith CB, White P, et al. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain: a journal of neurology. 1976; 99(3): 459-496.
Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J. 1978; 2(6150): 1457-1459.
Bartus RT, Dean III RL, Beer B, & Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982; 217(4558): 408-414.
Holttum JR, Gershon S. The cholinergic model of dementia, Alzheimer type: progression from the unitary transmitter concept. Dementia and Geriatric Cognitive Disorders. 1992; 3(3): 174-185.
Tariot PN, Farlow MR, Grossberg GT, et al. Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291(3): 317-24.
Van Dyck CH, Tariot PN, Meyers B, et al. For the Memantine MEM-MD-01 Study Group. A 24- week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007; 21 (2): 136-43.
Shlesinger JB. Buluş nasıl yapılır? Çeviri Ergin Ö, TÜBÍTAK Yayim, Ankara. 1996; s.19.
Temel psikofarmakoloji. Yüksel N, Soygür H, Tural Ü ve ark. Ankara, Türkiye Psikiyatri Derneği 1, 2010.
Ayd FJ, Blackwell B. Discoveries in biological psychiatry. FJAyd, B Blackwell (Eds),Philadelphia, Lippincott. 1970; 218-229.
Ruiz P. Comprehensive textbook of psychiatry B. J. Sadock, & V. A. Sadock (Eds.). Philadelphia: lippincott Williams & wilkins. 2000; 1: 938-950.
Jeste DV, Gillin JC, Wyatt RJ. Serendipity in biological psychiatry—A myth?. Archives of General Psychiatry. 1979; 36(11): 1173-1178.
